13 mai, 2009

SENZATIONAL!!!!!1 - Realitatea TV & .NET, sinucidere a profesionalismului inDirect. ATENŢIE - IMAGINI ŞOCANTE!

Atentie, nu schimbaţi canalul, urmează un comunicat important pentru ţara!

EXCLUSIV! Danezia lucreaza chiar acum la noul design al portalului iRealitatea care sa asigure dominatia si suprematia in topul siteurilor de stiri din univers.

Pornisem cu gandul sa public o mica urecheala celor de la Realitatea cu privire la prostiile pe care incep sa le debiteze in incercarea dispearata de a face audienta cu orice pret. asa... ca sa se vada si feedbackul poporului la sefii de la post.

Din pacate, am intrat pe site si m-am enervat atat de tare de manelizarea, tabloidizarea si senzationalismul desantat de pe site, incat trebuie sa scriu acest articol.

Inteleg... ca ziceti de 500.000 de morti in Bucuresti dupa orice cutremur, inteleg ca va panicati cand vine vorba de gripa porcina (nu aveti consultanti pe acolo.... asa ca tonul stirilor e din ce in ce mai mult o medie a starilor emotionale din redactie... decat unul logic, calculat... profesionist)

Inteleg... si zbieretele cand vine vorba de siguranta aviatica in Romania, exagerati desigur... dar situatia nu e desigur roz si un accident aviatic major sta sa se intample. Insa nu tipetele ci jurnalismul de investigatie sunt solutia...

Insa nu pot ierta ca pentru voi... actualitatea inseamna Becali, fotbal si hapciu...

asa... cum mi se pare inacceptabila absenta totala a jurnalismului real de investigatie (ProTV-ul face reportaje superbe de exemplu), si mai ales abundenta de articolase de prost gust de pe portalul Realitatea.net

O alandala de filmulete (deseori violente si obscente) de pe Youtube, barfe despre vedete... supozitii... articole "stiintifice" din cele mai bizare si prost informate.

In plus...

Nu e asa de bine sa stai toata ziua cu criza in gura? Uite ca am si eu o criza de dispozitie... dar parca nu ar fi decent sa o exprim chiar acum in cuvinte.... (inca cred ca am fost bine crescut)

(privit din nou pe siteul Realitatea.net)


Hmmm... sau poate ca pot sa ma exprim, nu de alta dar siteul nr. 1 din Romania a avut grija sa imi stabileasca cu grija limitele responsabilităţii jurnalistice!

Realitatea TV... iti urez "Pula non stop".
De astazi m-ai pierdut de cititor si privitor.

Cu respect,
Mihai

Citeste tot articolul si Comentariile!

11 mai, 2009

Filme noi Mai 2009

Un inceput exceptional de luna cu Wolverine si un blockbuster solid, un super film: Star Treck.

Urmeaza:

  • @15, Angels & Demons (Ingerii si Demonii ce continua aberatiile din Codul lui Da Vinci). RAU, pentru OTV-isti.
  • @21,Terminator Salvation, fara Arnold, "terminatoarele" nu mai au famerc, cred ca o sa il vad chiar daca presimt un film MEDIOCRU
  • @22, Dance Flick, inca un film din seria parodiilor pentru idioti (Epic Movie etc..), garantat FOARTE PROST.
  • @29, UP, cei de la PIXAR sunt imperturbabili la capitolul calitate. Un film BUN, dar sincer sunt satul de animatii.

Citeste tot articolul si Comentariile!

Filmele verii 2009

Un mic sumar al celor mai asteptate sau... detestate film ce vor avea premiera in aceasta vara.


MAI 2009

IUNIE 2009

IULIE 2009

AUGUST 2009

Pe masura aproprieri datei premierei... vor aparea informatii aditionale cu privire la mult mai multe filme interesante... cat si destule informatii sigure pentru clasificarea BUN / RAU

Citeste tot articolul si Comentariile!

10 mai, 2009

Cronica TV - Formula 1 cu Mihai Marinescu

O duminica perfecta e cea in care se desfasoara o cursa de Formula 1 la o ora rezonabila... dupa papica si berica, nu e nimic mai frumos decat sa atipesti vreo doua ore in zgomotul motoarelor...
F1 nu e un sport spectaculos decat atunci cand ploua, in rest invarteala monotona de vreo doua ore se poate viziona printre episoade de somnic fara a pierde mare lucru. Esti atent la start, la schimburile de pneuri si la finalul cursei... si lasi sonorul destul de tare astfel incat sa te trezeasca orice incident....

In rest somn de voie atunci cand Miki vorbeste din amintiri sau despre pilotii romani.

Din pacate in aceasta duminica, chiar daca cursa a devenit foarte plictisitoare pe la mijloc... comentariu a fost neasteptat de vioi si interesat, Victor Bonifaciu incercnd sa modereze schimburi de replici destul de interesante intre Mihai Alexandrescu si Mihai Marinescu.

Ultimul dintre cei doi e chiar atent la cursa, are comentarii la punct... interpreteaza corect comunicatele radio... WOW!!!, in timp ce Miki bate campii ca de obicei, mai mult cu mondenitati.

Trioul asta e dupa mine perfect: Bonifaciu comentatori, moderator... Marinescu, tanarul pilot atent la partea tehnica si la cursa in general (foarte interesant), Miki chibitul... cu partea de mondenitati, fete, baieti, aberatii in general... mult mai hazliu atunci cand bate apropouri la Marinescu (talent, curse, fete).

Sincer nu imi doresc acum decat ca Marinesc sa fie o prezenta permanante in comentariu F1 la TVR. Asa poate mai face rost si notorietate, bani, benzina si cauciucuri pentru cateva curse.

Baiatul are curaj, voce placuta, e vorbaret si dupa ce isi da drumul il contrabalaseaza perfect pe Miki.

... poate daca TVR face asta, ii iert pentru mutarea jurnalului la 20:00

Citeste tot articolul si Comentariile!

08 mai, 2009

Star Trek - 9/10

.J. Abrams avea toate sansele din lume sa esueze lamentabil, insa a reusit imposibilul. Star Trek nu a aratat niciodata mai bine, mai incitant si mai captivant! Un film pe masura tuturor asteptarilor ce dezamageste doar la capitolul coloana sonora (lamentabila, bubuita si monotona)

Nici nu trec 5 minute si lumea intreaga a universului Star Trek se rastoarna cu fundul in sus, lasand fanii cu gura cascata si lipsiti de orice fel de cunostinte. Decenii de seriale, filme, carti canonice sau mai putin canonice isi pierd importanta... prin acest restart brutal al acestui univers ce nu poate fi decat e o idee geniala. Singura care de altfel mai putea salva o franciza imbatranită si sufocata de propriile ei canoane.

Suntem in copilaria federatiei si descoperim cu placere bucatele din trecut (prezentul nostru) ce se impletesc cu viitorul. O masina clasica... urmarita e o motocicleta zburatoare, campuri imense... din care rasar citadele urbane ce strapung cerul, imagine impresionanta ce e completata de tehnologii ciudate dar care par sa aiba urme de familiaritate.

Suntem introdusi rapid cu marea majoritate a personajelor TOS, si repejor lumea "noului" Star Trek se distanteaza violent de tot ceea ce cunosteam odata ce vulcanienii si planeta lor sufera un "minor" colaps cuantic al spatiu-timpului catre singularitate.

Inainte si dupa chestia asta vedem superbe batalii spatiale + niste animalute foarte dragute pe o planeta indepartata, ce apuca sa ne duca deseori cu gandul la tot ceea ce e mai bun in "Star Wars". De fapt nu m-ar fi surprins daca la un moment dat lumea ar fi scos si niste sabii cu laser pentru o mica cafteala... mai ales ca de sabii obisnuite avem totusi parte.

Problemele care stau intre acest film si perfectiune sunt urmatoarele:

  • coloana sonora ce este absolut neinspirata si deloc pe masura filmului (ca o nota... efectele sonore sunt totusi geniale si imi place boomul pe care il fac navele cand intra in hyperspatiu)
  • anumite gogomanii stiintifice ce nu pot fi iertate chiar daca Star Trek nu a avut niciodata pretentii in acest domeniu: chestia aia rosie... careia ii zic "substanta rosie" bleah... macar de era "trilitiu", "materie exotica", "supa de quarki, bosoni" whatever..., gaurile negre nerealistice si nerelativiste, cat despre calatorii in timp, mai bine nici nu mai deschidem subiectul (calatoriile in timp au fost tot timpul problematice in Star Trek.
  • sala motoarelor din Enterprize (cat si alte nave ale Federatiei), am vazut fabrici de ciocolata, cuie, surubelnite si creione mai tehnologice si avansate decat tevile si rezervoarele de inox din film, absolut jenant chiar daca puntea navei este ireprosabil de futurista (si se aseamana foarte mult cu cea din TOS).
In rest... numai de bine, un blockbuster solid ce o sa faca ravagii in box-office. Filmul pe fanii mai tineri si l-au dorit dintotdeauna.

Ma bucur atat de mult sa vad Star trek salvat de la imbatrnire si ridicol, si de abia astept sa vad noi aventuri cu acest echipaj, intr-un univers lipsit de canoane... si in care nu trebuie respectata continuitatea cu nici o alta serie, film sau carte!

Dulcele aer proaspat al libertatii in creativitate nu a mai mirosit niciodata mai bine... sau mai incurajator!

Nota importanta!

Health and safety warning!
Acest film ruleaza in unele cinematografele de pe la noi cu sonorul la nivel exagerat, nivel ce creaza un puternic disconfort si poate crea probleme de auz.

Danezia ii roaga pe toti cei care sunt deranjati de astfel de "tactici" manelistice ale managerilor de sali de cinema sa ii manifeste nemultumirea atat verbal (personalului salii de cinema) cat si in scris firmei ce administreaza respectiva sala

Citeste tot articolul si Comentariile!

Star Trek (2009) - calatorie la cinema + review in aceasta seara...

Noul Star Trek promite actiune, dinamism si un binemeritat restart al intregii francize, si toate cronicile (inclusiv cele moderat negative sau neutre) sunt de parere ca filmul isi atinge cu succes obiective.


Tocilarul din mine, fan inrait Star Trek arde de nerabdare sa vada acest film in conditii adecvate... asa ca voi fi la cinema in aceasta seara.

Sunt atat de curios daca filmul o sa fie la fel de interesant si pentru prietena mea. Nu de alta dar 35% din nota mea pentru creatia lui J.J. Abrams va depinde si de reactia ei.

It better be cool, it better not be boring!
Promit sa fiu live pe twitter, si sper sa nu ma distraga cateva postari... iar daca chiar nu o sa postez nimic pana la final, asta chiar o sa insemna ca filmul e distractiv si captivant.

Citeste tot articolul si Comentariile!

Copy Paste (CDCemegency) Ghid interimar de utilizare a medicamentelor antivirale

Din cauza absentei totale de obiectivitate si credibilitate a istericei mass-medii romanesti, sunt nevoit sa postez din nou despre gripa H1N1, pentru ca riscul aparitiei unei tulpini mai agresive este cat se poate de real

Sursa e aici si recomandarea mea e sa urmariti cu atentie si sa monitorizati cu calm situatia. Pe masura ce antiviralele vor deveni din nou disponibile, cumparati cu incredere si printati orice instructiuni speciale de folosire... asa cum este si cea de mai jos.

Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and Their Close Contacts

May 6, 2009 11:00 PM ET
Objective: To provide updated interim guidance on the use of antiviral agents for treatment and chemoprophylaxis of novel influenza (H1N1) virus infection, and assist clinicians in prioritizing use of antivirals for treatment or chemoprophylaxis of patients at higher risk for influenza-related complications. Additional revisions to these recommendations for antiviral treatment should be expected as the epidemiology and clinical presentation of novel influenza A (H1N1) virus infection is better understood. This guidance can be adapted according to local epidemiologic data and antiviral supply considerations.
High-risk groups: A person who is at high-risk for complications of novel influenza (H1N1) virus infection is defined as the same for seasonal influenza at this time. As more epidemiologic and clinical data become available, these risk groups might be revised.
  • Children younger than 5 years old. The risk for severe complications from seasonal influenza is highest among children younger than 2 years old.
  • Adults 65 years of age and older.
  • Persons with the following conditions:
  • Chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematological (including sickle cell disease), neurologic, neuromuscular, or metabolic disorders (including diabetes mellitus);
  • Immunosuppression, including that caused by medications or by HIV;
  • Pregnant women;
  • Persons younger than 19 years of age who are receiving long-term aspirin therapy;
  • Residents of nursing homes and other chronic-care facilities.
Transmission: Transmission of novel influenza A (H1N1) is being studied as part of the ongoing outbreak investigation, but limited data available indicate that this virus is likely transmitted in ways similar to other influenza viruses. Seasonal human influenza viruses are thought to be transmitted between persons primarily through large-particle respiratory droplet transmission (e.g., when an infected person coughs or sneezes near a susceptible person). Transmission via these large-particle droplets requires close contact between source and recipient persons because droplets do not remain suspended in the air and generally travel only a short distance (<>
Close contact, for the purposes of this document, is defined as having cared for or lived with a person who is a confirmed, probable or suspected case of novel influenza A (H1N1), or having been in a setting where there was a high likelihood of contact with respiratory droplets and/or body fluids of such a person. Examples of close contact include kissing or embracing, sharing eating or drinking utensils, physical examination, or any other contact between persons likely to result in exposure to respiratory droplets. Close contact typically does not include activities such as walking by an infected person or sitting across from a symptomatic patient in a waiting room or office.
Special Considerations for Children
Aspirin or aspirin-containing products (e.g. bismuth subsalicylate – Pepto Bismol) should not be administered to any confirmed or suspected ill case of novel influenza H1N1 virus infection aged 18 years old and younger due to the risk of Reye syndrome. For relief of fever, other anti-pyretic medications such as acetaminophen or non- steroidal anti-inflammatory drugs are recommended.
Children younger than 4 years of age should not be given over-the-counter cold medications without first speaking with a healthcare provider.

Antiviral Resistance

This novel (H1N1) influenza virus is sensitive (susceptible) to the neuraminidase inhibitor antiviral medications, zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine.

Antiviral Treatment for Novel (H1N1) Influenza

For antiviral treatment of novel influenza (H1N1) virus infection, either oseltamivir or zanamivir are recommended Table 1. Recommendations for use of antivirals may change as data on antiviral effectiveness, clinical spectrum of illness, adverse events from antiviral use, and antiviral susceptibility data become available.
Clinical judgment is an important factor in treatment decisions. Persons with suspected novel H1N1 influenza who present with an uncomplicated febrile illness typically do not require treatment unless they are at higher risk for influenza complications, and in areas with limited antiviral mediation availability, local public health authorities might provide additional guidance about prioritizing treatment within groups at higher risk for infection.
Treatment is recommended for:
  1. All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1).
  2. Patients who are at higher risk for seasonal influenza complications (see above).
If a patient is not in a high-risk group or is not hospitalized, healthcare providers should use clinical judgment to guide treatment decisions, and when evaluating children should be aware that the risk for severe complications from seasonal influenza among children younger than 5 years old is highest among children younger than 2 years old. Many patients who have had novel influenza (H1N1) virus infection, but who are not in a high-risk group have had a self-limited respiratory illness similar to typical seasonal influenza. For most of these patients, the benefits of using antivirals may be modest. Therefore, testing, treatment and chemoprophylaxis efforts should be directed primarily at persons who are hospitalized or at higher risk for influenza complications.
Once the decision to administer antiviral treatment is made, treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of symptoms. Evidence for benefits from antiviral treatment in studies of seasonal influenza is strongest when treatment is started within 48 hours of illness onset. However, some studies of oseltamivir treatment of hospitalized patients with seasonal influenza have indicated benefit, including reductions in mortality or duration of hospitalization even for patients whose treatment was started more than 48 hours after illness onset. Recommended duration of treatment is five days. Antiviral doses recommended for treatment of novel H1N1 influenza virus infection in adults or children 1 year of age or older are the same as those recommended for seasonal influenza (Table 1). Oseltamivir use for children <1 href="http://www.cdc.gov/h1n1flu/recommendations.htm?s_cid=tw_epr_124#table2">Table 2) (See Emergency Use Authorization of Tamiflu (oseltamivir)).
Note: Areas that continue to have seasonal influenza activity, especially those with circulation of oseltamivir-resistant seasonal human influenza A (H1N1) viruses, might prefer to use either zanamivir or a combination of oseltamivir and rimantadine or amantadine to provide adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human influenza A (H1N1) virus infection.

Antiviral Chemoprophylaxis for Novel (H1N1) Influenza

For antiviral chemoprophylaxis of novel (H1N1) influenza virus infection, either oseltamivir or zanamivir are recommended (Table 1). Duration of antiviral chemoprophylaxis post-exposure is 10 days after the last known exposure to novel (H1N1) influenza. The indication for post-exposure chemoprophylaxis is based upon close contact with a person who is a confirmed, probable or suspected case of novel influenza A (H1N1) virus infection during the infectious period of the case. The infectious period for persons infected with the novel influenza A (H1N1) virus is assumed to be similar to that observed in studies of seasonal influenza. With seasonal influenza, studies have shown that people may be able to transmit infection beginning one day before they develop symptoms to up to 7 days after they get sick. Children, especially younger children, might potentially be infectious for longer periods. However, for this guidance, the infectious period is defined as one day before until 7 days after the case’s onset of illness. If the contact occurred with a case whose illness started more than 7 days before contact with the person under consideration for antivirals, then chemoprophylaxis is not necessary. For pre-exposure chemoprophylaxis, antiviral medications should be given during the potential exposure period and continued for 10 days after the last known exposure to a person with novel (H1N1) influenza virus infection during the cases infectious period. Oseltamivir can also be used for chemoprophylaxis under the EUA for children less than 1 year of age (see Children Under 1 Year of Age).
Post exposure antiviral chemoprophylaxis with either oseltamivir or zanamivir can be considered for the following:
  1. Close contacts of cases (confirmed, probable, or suspected) who are at high-risk for complications of influenza
  2. Health care personnel, public health workers, or first responders who haves had a recognized, unprotected close contact exposure to a person with novel (H1N1) influenza virus infection (confirmed, probable, or suspected) during that person’s infectious period. Information on appropriate personal protective equipment is available at: Interim Guidance for Infection Control for Care of Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection in a Healthcare Setting and might be updated frequently as additional information on transmission becomes available.
Pre-exposure antiviral chemoprophylaxis should only be used in limited circumstances, and in consultation with local medical or public health authorities. Certain persons at ongoing occupational risk for exposure who are also at higher risk for complications of influenza (e.g., health care personnel, public health workers, or first responders who are working in communities with influenza A H1N1 outbreaks) should carefully follow guidelines for appropriate personal protective equipment or consider temporary reassignment.

Antiviral Use for Control of Novel H1N1 Influenza Outbreaks

Use of antiviral drugs for treatment and chemoprophylaxis of influenza has been a cornerstone for the control of seasonal influenza outbreaks in nursing homes and other long term care facilities. (see MMWR: Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008). At this time, no outbreaks of novel influenza A (H1N1) have been reported in such settings. However, if such outbreaks were to occur, it is recommended that ill patients be treated with oseltamivir or zanamivir and that chemoprophylaxis with either oseltamivir or zanamivir be started as early as possible to reduce the spread of the virus as is recommended for seasonal influenza outbreaks in such settings. Chemoprophylaxis should be administered to all non-ill residents and should continue for a minimum of 2 weeks. If surveillance indicates that new cases continue to occur, chemoprophylaxis should be continued until approximately 7 days after illness onset in the last patient. In addition to antiviral medications, other outbreak-control measures include appropriate infection control, establishing cohorts of patients with confirmed or suspected influenza, restricting staff movement between wards or buildings, and restricting contact between ill staff or visitors and patients, and active surveillance for new cases. Medical directors of long-term care facilities should review their plans for outbreak control of influenza. Additional guidance for infection control measures in long-term care facilities can be found at: Using Antiviral Medications to Control Influenza Outbreaks in Institutions .
In addition to use in nursing homes, antiviral chemoprophylaxis also can be considered for controlling influenza outbreaks in other closed or semiclosed settings (e.g., correctional facilities, or other settings in which persons live in close proximity). For more information about influenza outbreaks in facilities see: Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008 or
Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaExternal Web Site Policy..
Table 1. Antiviral medication dosing recommendations for treatment or chemoprophylaxis of novel influenza A (H1N1) infection. (Table extracted from IDSA guidelines for seasonal influenzaExternal Web Site Policy..)
Agent, group Treatment Chemoprophylaxis
Oseltamivir
Adults 75-mg capsule twice per day for 5 days 75-mg capsule once per day
Children (age, 12 months or older), weight: 15 kg or less 60 mg per day divided into 2 doses 30 mg once per day
15-23 kg 90 mg per day divided into 2 doses 45 mg once per day
24-40 kg 120 mg per day divided into 2 doses 60 mg once per day
>40 kg 150 mg per day divided into 2 doses 75 mg once per day
Zanamivir
Adults Two 5-mg inhalations (10 mg total) twice per day Two 5-mg inhalations (10 mg total) once per day
Children Two 5-mg inhalations (10 mg total) twice per day (age, 7 years or older) Two 5-mg inhalations (10 mg total) once per day (age, 5 years or older)

Children Under 1 Year of Age

Children under one year of age are at high risk for complications from seasonal human influenza virus infection. The characteristics of human infection novel (H1N1) influenza virus are still being studied, and it is not known whether infants are at higher risk for complications associated with novel (H1N1) influenza virus infection compared to older children and adults. Oseltamivir is not licensed for use in children less than 1 year of age. However, limited safety data on oseltamivir treatment for seasonal influenza in children less than one year of age suggest that severe adverse events are rare.
Because infants experience high rates of morbidity and mortality from influenza, infants with novel (H1N1) influenza virus infections may benefit from treatment using oseltamivir. (Tables 2 and 3, Emergency Use Authorization of Tamiflu (oseltamivir) ).
Table 2. Dosing recommendations for antiviral treatment of children younger than 1 year using oseltamivir.
Age Recommended treatment dose for 5 days
<3> 12 mg twice daily
3-5 months 20 mg twice daily
6-11 months 25 mg twice daily
Table 3. Dosing recommendations for antiviral chemoprophylaxis of children younger than 1 year using oseltamivir.
Age Recommended prophylaxis dose for 10 days
<3> Not recommended unless situation judged
critical due to limited data on use in this age group
3-5 months 20 mg once daily
6-11 months 25 mg once daily
Healthcare providers should be aware of the lack of data on safety and dosing when considering oseltamivir use in a seriously ill young infant with confirmed novel (H1N1) influenza virus infection or who has been exposed to a confirmed novel (H1N1) influenza case, and carefully monitor infants for adverse events when oseltamivir is used. Additional information on oseltamivir for this age group can be found at: Swine Flu: Emergency Use Authorization (EUA) of Medical Products and Devices.

Pregnant Women

Pregnant women are known to be at higher risk for complications from infection with seasonal influenza viruses, and severe disease among pregnant women was reported during past pandemics. Cases of confirmed novel (H1N1) influenza virus infection in pregnant women resulting in severe disease have been reported, and a pregnant woman died in 1988 after being infected with another type of swine influenza virus. Oseltamivir and zanamivir are "Pregnancy Category C" medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women. Although a few adverse effects have been reported in pregnant women who took these medications, no relation between the use of these medications and those adverse events has been established. Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Because of its systemic activity, oseltamivir is preferred for treatment of pregnant women. The drug of choice for chemoprophylaxis is less clear. Zanamivir may be preferable because of its limited systemic absorption; however, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems.

Adverse Events and Contraindications

For further information about influenza antiviral medications, including contraindications and adverse effects, please see the following:
Adverse events from influenza antiviral medications should be reported through the U.S. FDA Medwatch websiteExternal Web Site Policy..

Citeste tot articolul si Comentariile!

05 mai, 2009

Verdict: Gripa Porcina, H1N1 (tulpina mexicana) nu e cu nimic mai agresiva decat gripa sezoniera...

 Editare, 10 ianuarie 2009

Pentru a preveni orice confuzii articolul se refera la o situatie din trecut... si a fost valabil pentru acea situatie

Intre timp virusul a suferit o mutatie in Ucraina, mutatie ce il face periculos si cu un procent de mortalitate de peste 2%.

Deoarece urmaresc virusul inca de la primele cazuri din Mexic, am inteles pericolul si m-am vaccinat la inceputul lunii Decembrie (sunt printre primii romani vaccinati). Intre timp am convins si pe altii ca trebuie sa se vaccineze.

Puteti citi despre vaccin, efectele sale si de ce trebuie sa va vaccinati pe blogul meu dedicat acestei probleme:

Cantgrip, Eu si AH1N1


 Articolul original (datat 5 mai 2009):
covorase cu dezinfectant... reporteri si moderatori ce tot intreaba cand e timpul sa intram in panica... masti pe fata, Tamiflu retras din farmacii... si brosurele tiparite de baietii destepti pe banii nostrii: Totul pentru un mare fas!


Tulpina actuala de gripa H1N1 e jenant de neagresiva. Nu se ridica nici macar la nivelul ultimelor pandemii serioase din 57, 68 ca sa nu vorbim de 1918.

Apropo H1N1 nu e chiar o mare descoperire... si exista ceva imunitate la chestiuta asta avand in vedere ca tot H1N1 a fost si gripa spaniola...

Date tehnice A/H1N1... tulpina are 4 componenete specific umane, 1 bucata aviara si 2 bucati porcina, insa virusul asta care uneste toate cele 3 versiuni de gripa pare sa fie deocamdata inofensiv...

Insa acum tonul acestui articolas... se schimba...

Versiunea penibila a lui A/H1N1 si toata panica de fufe isterizate... o sa ne coste amarnic la iarna, cand versiunea completa si letala a virusului o sa fie probabil gata. Nu ma indoiesc ca odata ajuns in Asia virusul va suferi o noua mutatie in leaganul prea minunat al virusurilor gripale.

Insa lumea nu va fi pregatita, oamenii satui de virusaraie... si de prostiile de la TV nu se vor vaccina si vor lua in ras noile cazuri de gripa...

Iar gripa ce va veni... va fi cu adevarat agresiva, si va contamina intrega planeta in mai putin de o saptamana, si nu ne vom da seama de asta decat cand va fi prea tarziu.

Nota:

Odata de pandemia de isterie se va linisti, pregatiti un BOB sau GOOD la indemana... care sa contina Tamiflu (si.... in cel mai rau caz sau) Relenza... odata ce aceste medicamente vor fi din nou disponibile la vanzare.

Cititi modul de utilizare si nu ezitati sa le folositi in caz de pandemie.

Verificati din cand in cand... harta reala si completa a raspandirii virusului H1N1...

http://flutracker.rhizalabs.com/

si nu in ultimul rand, urmariti feedul meu de tweeter :), in mod sigur o sa gasiti informatii mai relevante si mai corecte decat cele de la televiziunile de pe la noi.

Citeste tot articolul si Comentariile!

01 mai, 2009

The Forbidden Kingdom - 6/10

E trist sa descoperi ca talentele combinate ale lui Jackie Chan si Jet Li se irosesc intr-un film mediocru.
Regatul interzis nu reprezinta decat o vaga tentativa gen "Lord of the Rings" presarata cu mitologie chineza. Cand adaugi la asta si baietasul din America, gen Karate Kid... aterizat la dreaq in praznic... ciorba e completa.

Verdict final: nimic deosebit la filmul acesta, divertisment bunicel si usor... dar care va fi uitat cu usurinta.

Citeste tot articolul si Comentariile!
 
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 Unported License.